AC Immune (ACIU)

• Market cap: $149M
• 1 day: -1.33%
• 5 days: 0.00%
• 1 month: -33.03%
• 3 months: -44.78%
• 6 months: -53.89%
• Year to date: -48.07%
• 1 year: -38.84%
• 5 years: -81.15%
• 10 years: -90.55%
• Sector: Healthcare
• Industry: Biotechnology

About: AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Employees: 172

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,957% more call options, than puts

Call options by funds: $144K | Put options by funds: $7K

38% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 8

5% more funds holding

Funds holding: 43 [Q3] → 45 (+2) [Q4]

0.83% less ownership

Funds ownership: 28.29% [Q3] → 27.46% (-0.83%) [Q4]

8% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 13

31% less capital invested

Capital invested by funds: $107M [Q3] → $73.9M (-$32.7M) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $16 981% upside
• Avg. target: $16 981% upside
• High target: $16 981% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Andrew Fein 27% 1-year accuracy 95 / 352 met price target

981% upside $16

Buy Reiterated

3 Apr 2025